Ionis Pharmaceuticals, Inc. Common Stock

IONSNasdaqCIK 874015Healthcare / Drug Manufacturersfiscal year ends December70 quarters since 2009

Revenue, Q3 FY2026
$243M
+54.9% on Q3 FY2025
Net income
−$110M
+14.5% on Q3 FY2025
Free cash flow
−$192M
−40.5% on Q3 FY2025
Diluted EPS
$-0.66
+17.5% on Q3 FY2025
Revenue, TTM
$960M
trailing four quarters
Net margin, TTM
-56.9%
net income −$547M
Free cash flow, TTM
−$616M
−$544M less $72M capex
Cash and equivalents
$296M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+2.8%
167M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$4.8B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 9, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Ionis Pharmaceuticals, Inc. Common Stock reported revenue of $243M, +54.9% on Q3 FY2025, and net loss of $110M (+14.5%). Operating margin was −53.8%. Free cash flow, operating cash flow less capital expenditures, was −$192M (−$179M less $13M). Diluted earnings per share were $-0.66.

Share price

Daily candlesticks from November 18, 2024 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

IONS daily priceSplit-adjusted, US dollars; an earnings release
Nov 13, 2026O $27.30 · H $29.09 · L $27.25 · C $29.06 · +6.41% on the dayOver the range: −58.39%, Nov 14, 2025 to Nov 13, 2026
$24$40$57$74$90Nov 25Jan 26Apr 26Jun 26Sep 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 9, 2026.

Revenue and net incomeRevenueNet income
−$400M−$200M$0$200M$400M$600MQ4'22, Revenue: $152MQ4'22, Net income: −$52MQ4'22Q1'23, Revenue: $131MQ1'23, Net income: −$124MQ1'23Q2'23, Revenue: $188MQ2'23, Net income: −$85MQ2'23Q3'23, Revenue: $144MQ3'23, Net income: −$147MQ3'23Q4'23, Revenue: $325MQ4'23, Net income: −$9MQ4'23Q1'24, Revenue: $119MQ1'24, Net income: −$143MQ1'24Q2'24, Revenue: $225MQ2'24, Net income: −$66MQ2'24Q3'24, Revenue: $134MQ3'24, Net income: −$140MQ3'24Q4'24, Revenue: $227MQ4'24, Net income: −$104MQ4'24Q1'25, Revenue: $132MQ1'25, Net income: −$147MQ1'25Q2'25, Revenue: $452MQ2'25, Net income: $124MQ2'25Q3'25, Revenue: $157MQ3'25, Net income: −$129MQ3'25Q4'25, Revenue: $203MQ4'25, Net income: −$229MQ4'25Q1'26, Revenue: $246MQ1'26, Net income: −$93MQ1'26Q2'26, Revenue: $268MQ2'26, Net income: −$115MQ2'26Q3'26, Revenue: $243MQ3'26, Net income: −$110MQ3'26−$400M−$200M$0$200M$400M$600MQ4'22, Revenue: $152MQ4'22, Net income: −$52MQ4'22Q1'23, Revenue: $131MQ1'23, Net income: −$124MQ1'23Q2'23, Revenue: $188MQ2'23, Net income: −$85MQ2'23Q3'23, Revenue: $144MQ3'23, Net income: −$147MQ3'23Q4'23, Revenue: $325MQ4'23, Net income: −$9MQ4'23Q1'24, Revenue: $119MQ1'24, Net income: −$143MQ1'24Q2'24, Revenue: $225MQ2'24, Net income: −$66MQ2'24Q3'24, Revenue: $134MQ3'24, Net income: −$140MQ3'24Q4'24, Revenue: $227MQ4'24, Net income: −$104MQ4'24Q1'25, Revenue: $132MQ1'25, Net income: −$147MQ1'25Q2'25, Revenue: $452MQ2'25, Net income: $124MQ2'25Q3'25, Revenue: $157MQ3'25, Net income: −$129MQ3'25Q4'25, Revenue: $203MQ4'25, Net income: −$229MQ4'25Q1'26, Revenue: $246MQ1'26, Net income: −$93MQ1'26Q2'26, Revenue: $268MQ2'26, Net income: −$115MQ2'26Q3'26, Revenue: $243MQ3'26, Net income: −$110MQ3'26−$400M−$200M$0$200M$400M$600MQ4'22, Revenue: $152MQ4'22, Net income: −$52MQ1'23, Revenue: $131MQ1'23, Net income: −$124MQ1'23Q2'23, Revenue: $188MQ2'23, Net income: −$85MQ3'23, Revenue: $144MQ3'23, Net income: −$147MQ3'23Q4'23, Revenue: $325MQ4'23, Net income: −$9MQ1'24, Revenue: $119MQ1'24, Net income: −$143MQ1'24Q2'24, Revenue: $225MQ2'24, Net income: −$66MQ3'24, Revenue: $134MQ3'24, Net income: −$140MQ3'24Q4'24, Revenue: $227MQ4'24, Net income: −$104MQ1'25, Revenue: $132MQ1'25, Net income: −$147MQ1'25Q2'25, Revenue: $452MQ2'25, Net income: $124MQ3'25, Revenue: $157MQ3'25, Net income: −$129MQ3'25Q4'25, Revenue: $203MQ4'25, Net income: −$229MQ1'26, Revenue: $246MQ1'26, Net income: −$93MQ1'26Q2'26, Revenue: $268MQ2'26, Net income: −$115MQ3'26, Revenue: $243MQ3'26, Net income: −$110MQ3'26

Net income losses drawn in red.

Free cash flow
−$1.0B−$500M$0$500M$1.0BQ4'22, Free cash flow: −$204MQ4'22Q1'23, Free cash flow: −$144MQ1'23Q2'23, Free cash flow: −$109MQ2'23Q3'23, Free cash flow: −$111MQ3'23Q4'23Q1'24, Free cash flow: −$154MQ1'24Q2'24, Free cash flow: −$126MQ2'24Q3'24, Free cash flow: −$124MQ3'24Q4'24, Free cash flow: −$142MQ4'24Q1'25, Free cash flow: −$163MQ1'25Q2'25, Free cash flow: $139MQ2'25Q3'25, Free cash flow: −$137MQ3'25Q4'25, Free cash flow: −$159MQ4'25Q1'26, Free cash flow: −$815MQ1'26Q2'26, Free cash flow: $549MQ2'26Q3'26, Free cash flow: −$192MQ3'26−$1.0B−$500M$0$500M$1.0BQ4'22, Free cash flow: −$204MQ4'22Q1'23, Free cash flow: −$144MQ1'23Q2'23, Free cash flow: −$109MQ2'23Q3'23, Free cash flow: −$111MQ3'23Q4'23Q1'24, Free cash flow: −$154MQ1'24Q2'24, Free cash flow: −$126MQ2'24Q3'24, Free cash flow: −$124MQ3'24Q4'24, Free cash flow: −$142MQ4'24Q1'25, Free cash flow: −$163MQ1'25Q2'25, Free cash flow: $139MQ2'25Q3'25, Free cash flow: −$137MQ3'25Q4'25, Free cash flow: −$159MQ4'25Q1'26, Free cash flow: −$815MQ1'26Q2'26, Free cash flow: $549MQ2'26Q3'26, Free cash flow: −$192MQ3'26−$1.0B−$500M$0$500M$1.0BQ4'22, Free cash flow: −$204MQ1'23, Free cash flow: −$144MQ1'23Q2'23, Free cash flow: −$109MQ3'23, Free cash flow: −$111MQ3'23Q1'24, Free cash flow: −$154MQ1'24Q2'24, Free cash flow: −$126MQ3'24, Free cash flow: −$124MQ3'24Q4'24, Free cash flow: −$142MQ1'25, Free cash flow: −$163MQ1'25Q2'25, Free cash flow: $139MQ3'25, Free cash flow: −$137MQ3'25Q4'25, Free cash flow: −$159MQ1'26, Free cash flow: −$815MQ1'26Q2'26, Free cash flow: $549MQ3'26, Free cash flow: −$192MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5BQ4'22, Cash and equivalents: $276MQ4'22, Long-term debt: $1.2BQ4'22Q1'23, Cash and equivalents: $309MQ1'23Q2'23, Cash and equivalents: $425MQ2'23Q3'23, Cash and equivalents: $352MQ3'23Q4'23, Cash and equivalents: $399MQ4'23, Long-term debt: $1.2BQ4'23Q1'24, Cash and equivalents: $349MQ1'24Q2'24, Cash and equivalents: $294MQ2'24Q3'24, Cash and equivalents: $335MQ3'24Q4'24, Cash and equivalents: $242MQ4'24, Long-term debt: $1.2BQ4'24Q1'25, Cash and equivalents: $264MQ1'25Q2'25, Cash and equivalents: $297MQ2'25Q3'25, Cash and equivalents: $338MQ3'25Q4'25, Cash and equivalents: $372MQ4'25, Long-term debt: $1.3BQ4'25Q1'26, Cash and equivalents: $173MQ1'26Q2'26, Cash and equivalents: $350MQ2'26Q3'26, Cash and equivalents: $296MQ3'26$0$500M$1.0B$1.5BQ4'22, Cash and equivalents: $276MQ4'22, Long-term debt: $1.2BQ4'22Q1'23, Cash and equivalents: $309MQ1'23Q2'23, Cash and equivalents: $425MQ2'23Q3'23, Cash and equivalents: $352MQ3'23Q4'23, Cash and equivalents: $399MQ4'23, Long-term debt: $1.2BQ4'23Q1'24, Cash and equivalents: $349MQ1'24Q2'24, Cash and equivalents: $294MQ2'24Q3'24, Cash and equivalents: $335MQ3'24Q4'24, Cash and equivalents: $242MQ4'24, Long-term debt: $1.2BQ4'24Q1'25, Cash and equivalents: $264MQ1'25Q2'25, Cash and equivalents: $297MQ2'25Q3'25, Cash and equivalents: $338MQ3'25Q4'25, Cash and equivalents: $372MQ4'25, Long-term debt: $1.3BQ4'25Q1'26, Cash and equivalents: $173MQ1'26Q2'26, Cash and equivalents: $350MQ2'26Q3'26, Cash and equivalents: $296MQ3'26$0$500M$1.0B$1.5BQ4'22, Cash and equivalents: $276MQ4'22, Long-term debt: $1.2BQ1'23, Cash and equivalents: $309MQ1'23Q2'23, Cash and equivalents: $425MQ3'23, Cash and equivalents: $352MQ3'23Q4'23, Cash and equivalents: $399MQ4'23, Long-term debt: $1.2BQ1'24, Cash and equivalents: $349MQ1'24Q2'24, Cash and equivalents: $294MQ3'24, Cash and equivalents: $335MQ3'24Q4'24, Cash and equivalents: $242MQ4'24, Long-term debt: $1.2BQ1'25, Cash and equivalents: $264MQ1'25Q2'25, Cash and equivalents: $297MQ3'25, Cash and equivalents: $338MQ3'25Q4'25, Cash and equivalents: $372MQ4'25, Long-term debt: $1.3BQ1'26, Cash and equivalents: $173MQ1'26Q2'26, Cash and equivalents: $350MQ3'26, Cash and equivalents: $296MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 9, 2026.

Ionis Pharmaceuticals, Inc. Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 9, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Jul 30, 2025Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue243268246203157452132227+54.9%
Cost of revenue33382414+42.1%
Gross profit—————————
Research and development—————————
Selling, general and administrative15415015013097917688+59.3%
Operating income(131)(102)(117)(214)(160)140(147)(111)+18.4%
Other income (expense)010(16)0000−23.7%
Pretax income(110)(113)(92)(228)(128)124(147)(107)+14.2%
Income tax0101000(3)−166.2%
Net income(110)(115)(93)(229)(129)124(147)(104)+14.5%
Diluted EPS ($)(0.66)(0.69)(0.56)(1.41)(0.80)0.70(0.93)(0.66)+17.5%
Diluted shares (millions)166165165—160182159——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 9, 2026.

Ionis Pharmaceuticals, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 9, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Jul 30, 2025Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents296350173372338297264242−12.4%
Short-term investments1,5881,7051,7462,3051,9021,9931,8812,056−16.5%
Total current assets2,3622,4912,9372,9912,5192,5772,4192,620−6.3%
Total assets2,9132,9953,4503,5243,0332,9852,8133,004−4.0%
Total current liabilities435316717782903897250309−51.8%
Long-term debt———1,328———1,202—
Total debt———1,812———1,253—
Total liabilities2,5192,5552,9593,0352,4152,3532,3372,415+4.3%
Stockholders’ equity394440491489618632476588−36.3%
Shares outstanding (millions)167166165165162159159159—

Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 9, 2026.

Ionis Pharmaceuticals, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 9, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Jul 30, 2025Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 19, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(179)566(793)(138)(131)151(151)(116)−36.5%
Capital expenditures131622215121325+141.2%
Free cash flow (CFO − capex)(192)549(815)(159)(137)139(163)(142)−40.5%
Depreciation and amortization44443333+50.7%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Ionis Pharmaceuticals, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Jul 30, 2025FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Mar 3, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Mar 1, 2011FY2009ended Dec 31, 2009filed Aug 9, 2010FY2008ended Dec 31, 2008filed Aug 9, 2010
Revenue9447057885878107291,12360051437328421414710299108122107
Cost of revenue161191411124200————————
Gross profit——————————————————
Research and development916902900—638531462412373340320239174155153145135106
Selling, general and administrative394267233150186354287245108493720151313121514
Operating income(382)(475)(354)(410)(30)(172)366(61)31(20)(76)(48)(52)(69)(71)(48)(28)(13)
Other income (expense)(15)114(7)(10)0(1)0(4)0————————
Pretax income(380)(460)(334)(258)(29)(135)339(76)(17)(57)(88)(54)(67)(75)(85)(61)(32)—
Income tax2(6)3212(1)34552(291)(6)30(15)(6)(9)003—
Net income(381)(454)(366)(270)(29)(444)2782740(60)(88)(39)(61)——(61)155(18)
Diluted EPS ($)(2.38)(3.04)(2.56)(1.90)(0.20)(3.18)1.902.070.15(0.50)(0.74)———(0.85)(0.62)1.58(0.19)
Diluted shares (millions)160150143142141140153134126121120—111101100999895

Balance sheet

Ionis Pharmaceuticals, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Jul 30, 2025FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Mar 3, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Mar 1, 2011FY2009ended Dec 31, 2009filed Aug 9, 2010FY2008ended Dec 31, 2008filed Aug 9, 2010
Cash and equivalents372242399276869398683279130851291431601246570105224
Short-term investments2,3052,0561,9321,7101,2461,4951,8161,805893581650586497250278402——
Total current assets2,9912,6202,6422,2032,3452,1312,7212,2081,169798837837736423360483596—
Total assets3,5243,0042,9902,5342,6122,3903,2332,6681,323912948956847546485550657—
Total current liabilities782309448312241599273280244134149115987476106111—
Long-term debt1,3281,2021,2411,176——————————————
Total debt1,8121,2531,3081,194—840788———————14915416—
Total liabilities3,0352,4152,6031,9611,8401,6461,5491,481957813747698469363313306355—
Stockholders’ equity4895883875737727431,4711,048281100201258378183171245292—
Shares outstanding (millions)165159146143142141139138125124121119117102100100——

Cash flow statement

Ionis Pharmaceuticals, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Jul 30, 2025FY2024ended Dec 31, 2024filed Feb 19, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Mar 3, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Mar 1, 2011FY2009ended Dec 31, 2009filed Aug 9, 2010FY2008ended Dec 31, 2008filed Aug 9, 2010
Operating cash flow(269)(501)(308)(274)3136346603174(112)21———(115)(64)(108)212
Capital expenditures5145241612353114357882110131314
Free cash flow (CFO − capex)(320)(546)(331)(290)191315589139(119)13———(125)(77)(122)198
Depreciation and amortization121213171815141389————————
Share repurchases———00913400—————————
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$148K
1 purchases by 1 insider; officers and directors $148K
Sold, three months
$61K
2 sales by 2 insiders; officers and directors $61K
Bought, twelve months
$1M
3 purchases by 1 insider; officers and directors $1M
Sold, twelve months
$120M
107 sales by 18 insiders; officers and directors $120M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 10, 2026Hayden Michael RDirectoropen-market buyindirect5,000$29.64$148K27,000Nov 13, 2026
Oct 16, 2026Devers Shannon L.EVP, Chief Human Resources Ofcopen-market sale1,357$43.54$59K17,811Oct 19, 2026
Oct 16, 2026Swayze EricEVP Researchopen-market saleindirect53$43.54$2K390Oct 19, 2026
Oct 15, 2026Devers Shannon L.EVP, Chief Human Resources Ofcoption exercise2,820$0.00—19,168Oct 19, 2026
Oct 15, 2026Swayze EricEVP Researchoption exerciseindirect125$0.00—443Oct 19, 2026
Aug 31, 2026Bennett C FrankEVP, Chief Scientific Officerother110$51.31$6K60,128Sep 2, 2026
Aug 31, 2026O'Neil Patrick R.EVP CLO & General Counselother63$51.31$3K59,205Sep 2, 2026
Aug 31, 2026Monia Brett PChief Executive Officer, Directorother98$51.31$5K242,760Sep 2, 2026
Aug 31, 2026Birchler BrianEVP, Corp and Development Opsother58$51.31$3K102,883Sep 2, 2026
Jul 31, 2026Hayden Michael RDirectoropen-market buyindirect5,000$51.60$258K24,000Jul 31, 2026
Jul 30, 2026Hayden Michael RDirectoropen-market buyindirect15,000$53.38$801K19,000Jul 31, 2026
Jul 15, 2026Herman Joan EDirectoroption exercise5,220$0.00—51,306Jul 17, 2026
Jul 15, 2026Berthelsen Spencer RDirectoroption exercise5,220$0.00—161,233Jul 17, 2026
Jul 7, 2026Bennett C FrankEVP, Chief Scientific Officeropen-market sale10b5-15,536$83.58$463K75,018Jul 9, 2026
Jul 7, 2026Bennett C FrankEVP, Chief Scientific Officerotherindirect15,000$0.00—15,000Jul 9, 2026
Jul 7, 2026Bennett C FrankEVP, Chief Scientific Officeropen-market sale10b5-1indirect15,000$85.46$1M0Jul 9, 2026
Jul 7, 2026Diaz Allene M.Directoroption exercise10,111$47.11$476K13,922Jul 9, 2026
Jul 7, 2026Diaz Allene M.Directoropen-market sale10b5-110,111$85.42$864K3,811Jul 9, 2026
Jul 7, 2026Kordasiewicz Holly B.EVP, Chief Development Officeropen-market sale10b5-1362$84.30$31K22,096Jul 9, 2026
Jul 1, 2026Klein Joseph IIIDirectoroption exercise11,518$39.94$460K22,532Jul 6, 2026
Jul 1, 2026Klein Joseph IIIDirectoropen-market sale10b5-199$79.45$8K22,433Jul 6, 2026
Jul 1, 2026Klein Joseph IIIDirectoropen-market sale10b5-111,419$79.04$903K11,014Jul 6, 2026
Jun 26, 2026Baroldi JosephEVP, Chief Business Officeroption exerciseindirect3,866$56.78$220K8,535Jun 30, 2026
Jun 26, 2026Baroldi JosephEVP, Chief Business Officeroption exerciseindirect1,769$32.60$58K10,304Jun 30, 2026
Jun 26, 2026Baroldi JosephEVP, Chief Business Officeropen-market sale10b5-1indirect5,635$80.16$452K4,669Jun 30, 2026

Full insider history for Ionis Pharmaceuticals, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held IONS in their latest 13F filing, through November 12, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded IONS by quarter.

FundManagerQuarterValueSharesWeightMove
Renaissance TechnologiesPeter BrownQ3 2026$16M354,2140.02%trimmed −36.7%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
IONIS PHARMACEUTICALS, INC., CIK 874015 on EDGAR
Extract generated
November 16, 2026
Withheld
5 line-years whose four quarters do not sum to the filed year: rnd FY2013, net income FY2016, operating income FY2016, revenue FY2016, net income FY2019
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: pretax income FY2021
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total debt: LongTermDebt, with finance leases
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 16, 2026.

JSON file
/data/financials/IONS.json